Cagrilintides potency on both receptors was found to be similar to their natural ligands, confirming its role as a balanced dual agonist
GLP-1 Agonist Semaglutide FDA-approved ~15% reported in trials Learn More Dual Agonist Tirzepatide FDA-approved ~21% reported in trials Learn More Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors
after reconstitution, refrigerate at 28C Related Research Peptides Researchers studying the KLOW blend peptide may also explore related compounds available at MyGLP1Store, including GHRP-2, CJC-1295 No DAC + Ipamorelin, and our anti-aging research and skin, hair & nail research collections
Finally, our study focused on the role of the PPAR/--catenin-TCF-4 pathway, but other potential pathways and interactions may also play a role and warrant further investigation